Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 4/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.60 |
| ▸ | IGF1R | P08069 | 10/20 | 0.59 |
| ▸ | BRAF | P15056 | 3/20 | 0.54 |
| ▸ | INSR | P06213 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1791445 | 0.94 | CDK19 (0.67) | CDK19ALKEGFRERBB2IGF1R | |
| SCHEMBL1791360 | 0.89 | EGFR (0.63) | CDK19ALKEGFRERBB2IGF1R | |
| SCHEMBL1789490 | 0.89 | IGF1R (0.70) | CDK19ALKEGFRERBB2IGF1R | |
| SCHEMBL1791538 | 0.88 | IGF1R (0.59) | CDK19ALKEGFRERBB2IGF1R | |
| SCHEMBL1788597 | 0.87 | IGF1R (0.65) | CDK19ALKEGFRERBB2IGF1R | |
| SCHEMBL1790184 | 0.87 | EGFR (0.60) | CDK19ALKEGFRERBB2IGF1R | |
| SCHEMBL1789005 | 0.86 | IGF1R (0.69) | CDK19ALKEGFRERBB2IGF1R | |
| SCHEMBL1788570 | 0.86 | IGF1R (0.72) | CDK19ALKEGFRERBB2IGF1R | |
| SCHEMBL1790559 | 0.85 | EGFR (0.58) | CDK19ALKEGFRERBB2IGF1R | |
| SCHEMBL1787955 | 0.85 | EGFR (0.60) | CDK19ALKEGFRERBB2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051315-B2 | Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition | ABBVIE INC. (US) | 2015-06-09 | — | — | US | claimed |
| EP-2496574-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | Abbott Laboratories (US) | 2012-09-12 | — | — | EP | claimed |
| US-20110124632-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | claimed |
| WO-2011053476-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | claimed |
| US-9051315-B2 | Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2496574-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | Abbott Laboratories (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20110124632-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2011053476-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124632-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | PACSIN2, MAP4K2, MAP3K6 | CDK19 522/4885ALK 593/4885EGFR 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.